CSF Concentration of Crizotinib in Two ALK-Positive Non-Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment

J Thorac Oncol. 2015 May;10(5):e26-e27. doi: 10.1097/JTO.0000000000000468.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anaplastic Lymphoma Kinase
  • Antineoplastic Agents / cerebrospinal fluid*
  • Antineoplastic Agents / therapeutic use
  • Brain Neoplasms / cerebrospinal fluid
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / secondary
  • Carcinoma, Non-Small-Cell Lung / blood
  • Carcinoma, Non-Small-Cell Lung / cerebrospinal fluid*
  • Carcinoma, Non-Small-Cell Lung / secondary
  • Crizotinib
  • Humans
  • Lung Neoplasms / blood
  • Lung Neoplasms / cerebrospinal fluid*
  • Lung Neoplasms / drug therapy
  • Male
  • Meningeal Carcinomatosis / drug therapy*
  • Meningeal Carcinomatosis / secondary
  • Middle Aged
  • Pyrazoles / blood
  • Pyrazoles / cerebrospinal fluid*
  • Pyrazoles / therapeutic use
  • Pyridines / blood
  • Pyridines / cerebrospinal fluid*
  • Pyridines / therapeutic use
  • Receptor Protein-Tyrosine Kinases / analysis

Substances

  • Antineoplastic Agents
  • Pyrazoles
  • Pyridines
  • Crizotinib
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases